Prostate cancer gene scores add little beyond age in Black men
Adding genetic information to age improved a measure of prostate cancer prediction by 1.83% over 10 years in Black men, compared with age alone.
Our read
Biomarkers- Studied:
- Preprint: cohort study of Black and White men with genetic data, 10 years
- What changed:
- Adding genetic scores to age improved prostate cancer prediction by 1.83% over 10 years in Black men
- The catch:
- Deaths and unnecessary diagnoses with score-guided screening were not measured
Editor of record: Boris Djordjevic · AgingResearch.News
Black and White men with genetic data in the UK Biobank and Our Future Health cohorts were included in a prospective cohort study of prostate cancer prediction. The researchers tested genetic risk scores combined with age, family history, or both, using two-, five- and 10-year prediction periods.
Adding a score based on 269 DNA differences to age improved a measure of how well predictions distinguished future cases from noncases by 8.69–11.23% in White men across all three periods. In Black men, the improvement was statistically significant only over 10 years, at 1.83%. Models combining age and genetic risk achieved similar overall ability to distinguish cases from noncases in Black and White men.
Why it matters
Age-specific prostate cancer screening depends on deciding what level of predicted risk warrants further checks. The authors suggest higher thresholds may help prevent overdiagnosis—finding cancers that would never cause harm—in Black men.
Caveats
The prediction results leave open whether score-guided screening would reduce deaths or unnecessary diagnoses. They concern Black and White men in two UK cohorts, and the preprint has not been peer-reviewed.
The paper
University of Exeter
Research Square, Nov 11, 2026, Open access, Preprint, not yet peer-reviewed
Comments
Be the first to comment.